Kit of parts for treating urinary incontinence in mammals
Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.
1 . A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a bidcompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal
wherein said delivery is conducted under conditions such that a polymer precipitate forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.
2 . The method according to claim 1 wherein said biocompatible polymer is selected from the group consisting of cellulose acetate polymers, ethylene vinyl alcohol copolymers and polyacrylates.
3 . The method according to claim 2 wherein said biocompatible polymer is a cellulose acetate polymer or an ethylene vinyl alcohol copolymer.
4 . The method according to claim 1 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.
5 . The method according to claim 4 wherein said biocompatible solvent is dimethylsulfoxide.
6 . The method according to claim 1 wherein said contrast agent is a water insoluble contrast agent.
7 . The method according to claim 6 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, and barium sulfate.
8 . The method according to claim 1 wherein said contrast agent is a water soluble contrast agent.
9 . The method according to claim 8 wherein said water soluble contrast agent is metrizamide.
10 . The method according to claim 1 wherein said composition is delivered into the periurethral tissue via a cystoscope.
11 . A method for the delivery of a composition comprising a biocompatible polymer, a biocomparible solvent, and a water insoluble contrast agent to the periurethral tissue of the mammal which tissue already has deposited therein with an initial amount of this composition which method comprises
visualizing the position of the deposited composition in the periurethral tissue
delivering a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent to the periurethral tissue of the mammal containing said deposited composition
wherein said delivery is conducted under conditions such that additional polymer precipitate forms in situ in the periurethral tissue thereby further reducing urinary incontinence in the mammal.
12 . The method according to claim 11 wherein visualization is conducted by direct visualization, fluoroscopy or ultrasound.
13 . A kit of parts comprising:
a first member which is an embolic composition comprising a biocompatible polymer, a biocompatible solvent and a contrast agent; and
a second member which is a needle selected from the group consisting of a puncture needle and spinal needle.
14 . The kit of parts according to claim 13 wherein said biocompatible polymer is selected from the group consisting of cellulose acetates, ethylene vinyl alcohol copolymers, polyalkyl(C 1 -C 6 )acrylates, polyalkyl alkacrylates wherein the alkyl and the alk groups contain no more than 6 carbon atoms; and polyacrylonitrile.
15 . The kit of parts according to claim 14 wherein said biocompatible polymer is a cellulose acetate polymer or an ethylene vinyl alcohol copolymer.
16 . The kit of parts according to claim 14 wherein said biocompatible solvent is selected from the group consisting of dimethylsulfoxide, ethanol, and acetone.
17 . The kit of parts according to claim 16 wherein said biocompatible solvent is dimethylsulfoxide.
18 . The kit of parts according to claim 13 wherein said contrast agent is a water insoluble contrast agent.
19 . The kit of parts according to claim 18 wherein said water insoluble contrast agent is selected from the group consisting of tantalum, tantalum oxide, tungsten, and barium sulfate.
20 . A method for treating urinary incontinence in a mammal, which method comprises delivering a composition comprising a biocompatible polymer and a biocompatible solvent to the periurethral tissue of the mammal
wherein said delivery is conducted under conditions such that a polymer precipitate forms in situ in the periurethral tissue thereby reducing urinary incontinence in the mammal.